Full-Time

Manager Regulatory Affairs

Multiple Teams

Posted on 8/13/2025

Novanta

Novanta

1,001-5,000 employees

Provides core photonics for medical tech

No salary listed

Berlin, Germany

In Person

Willingness to travel to different NOVT locations and business partners - Up to 10% traveling time.

Category
Legal & Compliance (1)
Requirements
  • Long-term (8-12 years) of extensive and well-founded functional professional experience
  • Leadership experience is required
  • Completed studies in the natural sciences, engineering, medical or comparable field
  • Possess extensive expertise in regulatory affairs, with a specialized background in the medical device industry
  • Advanced training 'Manager Regulatory Affairs for Medical Devices'
  • Languages: English Level CEFR C1*, German Level CEFR B2*
  • Independent, Quality-oriented, reliable, and dependable
  • Self-motivated
  • Team player
  • Be able to effectively communicate with internal stakeholders, regulatory agencies, and external partners
  • Well-structured and systematic way of working
Responsibilities
  • Management of or responsibility for the compilation of approval-relevant documents including free sales certificates, legalizations, other declarations, and certificates
  • Management of or responsibility for compiling documents for documentation evaluations by notified bodies and competent authorities worldwide
  • Management of or responsibility for the control/acceptance of technical documentation as part of the conformity assessment procedure, assessment of compliance with the essential requirements, preparation, and release of declarations of conformity
  • Interface between the RA departments of customers, the notified body and authorities
  • Support for audits (customers/authorities and suppliers of medical devices) in coordination and cooperation with the QMR
  • Management of safety-related complaints in cooperation with the Medical Affairs team
  • Initiation and management of the processing of measures to maintain the QMS (e.g. process adaptation)
  • Initiation of innovation process
  • Strict compliance with the quality, occupational safety and environmental regulations
  • Implementation of the instructions of the quality / environmental management representative and the occupational safety specialist

Novanta designs and supplies core technology platforms for precision photonics used in medical devices and advanced industrial equipment. Its products are components and subsystems—such as lasers, optics, sensors, and imaging hardware—that OEMs integrate into their own machines. Unlike companies that sell end-user devices, Novanta focuses on providing the underlying photonics technology that OEMs build into products, enabling reliable performance and scalable manufacturing. The company differentiates itself through deep specialization in photonics and by growing through acquisitions, aligning its portfolio toward medical technology and precision industrial markets. Its goal is steady, long‑term growth by delivering proven core technologies that help customers develop better medical devices and industrial solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bedford, Texas

Founded

1968

Simplify Jobs

Simplify's Take

What believers are saying

  • Medical Solutions revenue grew 15% in Q1 2026; bookings surged 37% with 1.10 book-to-bill ratio.
  • AI data center applications growing 20% year-over-year, expanding addressable market beyond traditional surgical robotics.
  • Novanta deploys $1.5B acquisition capacity targeting medical technologies and bioprocessing through 2026.

What critics are saying

  • Intuitive Surgical's da Vinci 6 integrates in-house precision components, displacing Novanta's motion subsystems.
  • Tariffs and freight costs compress gross margins 100 basis points; manufacturing transfers delay M&A deployment.
  • Customer concentration in GPU drilling exposes 15% revenue cliff if Nvidia diversifies suppliers post-2026.

What makes Novanta unique

  • Precision motion control and force sensing enable next-generation surgical robotics with millimeter-level accuracy.
  • Novanta Growth System extracts synergies from acquisitions, sustaining 45%+ gross margins through disruptions.
  • Sole-source supplier for AI data center GPU drilling, capturing 15% of Q1 2026 revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company News

Yahoo Finance
Mar 26th, 2026
Novanta falls 17% after revenue miss in otherwise strong Q4 for electronic components sector

As Q4 earnings season concludes, the nine electronic components stocks tracked showed strong performance, with revenues beating analyst consensus estimates by 3%. Share prices rose 5.2% on average since results were announced. Novanta posted revenues of $258.3 million, up 8.5% year-on-year, but fell short of analyst expectations by 0.9%. The company delivered the weakest performance against estimates in the group, with significant EBITDA misses. Its stock has dropped 17.4% since reporting, currently trading at $117.59. Allient led the group, reporting revenues of $143.4 million, up 17.5% year-on-year and beating expectations by 7.5%. The company also exceeded EBITDA estimates. Its shares have risen 6.3% since reporting, trading at $66.01.

EU-Startups
Mar 18th, 2026
Barcelona's Health Lean Analytics raises over $2.4M to automate hospital data with AI

Health Lean Analytics, a Barcelona-based startup automating hospital data collection, has raised over €2.1 million in a financing round combining private capital and public funding. US-listed Novanta joined as a technology and strategic partner, securing board representation. The round included an oversubscribed €1.4 million seed funding from family offices Inderhabs, Namarel and Braincats, plus a participative loan from Spain's National Innovation Company. Founded in 2023, HLA develops AI-powered hospital operations platforms that passively capture real-time clinical and operational data, particularly in surgical suites. The startup's technology integrates with existing hospital systems, using large language models to transform data into actionable insights. The funding will support domestic consolidation and US market entry within 12 months, whilst strengthening R&D capabilities in data automation and AI.

Yahoo Finance
Mar 4th, 2026
Harvey Partners bets $36M on Novanta despite flat stock performance

Harvey Partners disclosed a new position in Novanta, acquiring 304,000 shares worth $36.17 million during the quarter ending 17 February 2026, according to an SEC filing. The stake now represents 3.21% of the fund's reportable assets under management. Novanta, which provides photonics, vision and precision motion components for medical and industrial applications, has seen its shares remain roughly flat over the past year at around $145, significantly underperforming the S&P 500's 16% gain. The company reported revenue of $980.6 million in 2025, up 3% year over year, but operating income fell to $94 million from $110.6 million, whilst net income dropped from $64.1 million to $53.8 million. CEO Matthijs Glastra said the company plans to improve margins and cash flow this year.

Yahoo Finance
Feb 26th, 2026
Novanta CEO sells $1.1M worth of shares under pre-arranged trading plan

Novanta CEO Matthijs Glastra sold 7,500 common shares worth approximately $1.09 million on 10 February 2026, according to an SEC Form 4 filing. Following the transaction, Glastra holds 57,367 shares directly and 54,382 shares indirectly through a trust, with direct holdings valued at $8.3 million. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in September 2025, indicating routine liquidity management rather than concerns about company performance. The transaction matches Glastra's largest trade size in his 10 sell-only transactions since February 2023. Novanta manufactures photonics, vision and precision motion components for medical and industrial sectors, reporting $960.31 million in trailing twelve-month revenue and employing 3,000 people.

Yahoo Finance
Feb 24th, 2026
Novanta posts record Q4 on 25% bookings surge, targets $1.5B medical tech M&A

Novanta Inc. reported record fourth-quarter revenue and a return to organic growth, driven by a 25% surge in bookings across all business units. The precision technology company benefited from AI-driven demand in robotics, serving as the sole-source supplier for precision drilling of high-density GPU boards. Medical technology now represents 53% of total sales, with double-digit growth in consumables. However, the company experienced margin pressure due to regional manufacturing transfers, creating a temporary 100 basis point headwind. For 2026, Novanta projects mid-single-digit organic growth and 100 basis points of gross margin expansion once manufacturing transfers complete by Q2. The company plans to deploy nearly $1.5 billion in acquisition capacity towards medical technologies and bioprocessing. Operating cash flow is forecast at $145 million to $185 million.

INACTIVE